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Abstract 
Background: Systemic inflammation is known to induce sickness behaviors, including decreased social interaction 
and pain. We have reported increased serum inflammatory cytokines in a rat model of repetitive strain injury (rats 
perform an upper extremity reaching task for prolonged periods). Here, we sought to determine if sickness behaviors 
are induced in this model and the effectiveness of conservative treatments.
Methods: Experimental rats underwent initial training to learn a high force reaching task (10 min/day, 5 days/week 
for 6 weeks), with or without ibuprofen treatment (TRHF vs. TRHF + IBU rats). Subsets of trained animals went on 
to perform a high repetition high force (HRHF) task for 6 or 12 weeks (2 h/day, 3 days/week) without treatment, or 
received two secondary interventions: ibuprofen (HRHF + IBU) or a move to a lower demand low repetition low force 
task (HRHF‑to‑LRLF), beginning in task week 5. Mixed‑effects models with repeated measures assays were used to 
assay duration of social interaction, aggression, forepaw withdrawal thresholds and reach performance abilities. One‑
way and two‑way ANOVAs were used to assay tissue responses. Corrections for multiple comparisons were made.
Results: TRHF + IBU rats did not develop behavioral declines or systemic increases in IL‑1beta and IL‑6, observed 
in untreated TRHF rats. Untreated HRHF rats showed social interaction declines, difficulties performing the operant 
task and forepaw mechanical allodynia. Untreated HRHF rats also had increased serum levels of several inflammatory 
cytokines and chemokines, neuroinflammatory responses (e.g., increased TNFalpha) in the brain, median nerve and 
spinal cord, and Substance P and neurokinin 1 immunoexpression in the spinal cord. HRHF + IBU and HRHF‑to‑LRLF 
rats showed improved social interaction and reduced inflammatory serum, nerve and brain changes. However, nei‑
ther secondary treatment rescued HRHF‑task induced forepaw allodynia, or completely attenuated task performance 
declines or spinal cord responses.
Conclusions: These results suggest that inflammatory mechanisms induced by prolonged performance of high 
physical demand tasks mediate the development of social interaction declines and aggression. However, persistent 
spinal cord sensitization was associated with persistent behavioral indices of discomfort, despite use of conservative 
secondary interventions indicating the need for prevention or more effective interventions.
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Background
Work-related repetitive strain injuries, also known as 
work-related musculoskeletal disorders (WMSDs), are 
a leading cause of chronic pain and physical disability 
worldwide [38], and are associated with a wide range of 
inflammatory and degenerative diagnoses [62]. Their 
etiology in the upper extremity is multifactorial, and 
includes physical, individual, job and social cultural fac-
tors [18, 33, 52]. Key physical risk factors include high 
repetition, high force, cumulative exposure and inad-
equate recovery times between exposures [33]. These 
disorders are associated with increased sickness absence, 
depression and chronic pain, and accounted for 32% of 
all lost work time in the US in 2015 [11, 23]. Biobehavio-
ral mechanisms underlying work related depression and 
chronic pain changes are still under investigation [29], as 
are effective interventions [50, 58, 72].
Sickness behaviors, also known as Systemic Inflamma-
tory Response Syndrome, are a constellation of physio-
logical and behavioral responses that include depression, 
social withdrawal, allodynia and more [14, 73]. Sickness 
behaviors can be induced in animal models by admin-
istration of exogenous inflammatory cytokines either 
peripherally or centrally [48, 54]. Peripherally increased 
pro-inflammatory cytokines provoke central nervous 
system (CNS) neuroinflammation via several mecha-
nisms: diffusion from the circulatory system into the 
brain through blood brain barrier deficient areas; active 
transport by endothelial cells; activation of blood brain 
barrier or endothelial cells that then activate neurons and 
glia; and retrograde transport of afferent nerve signals 
centrally [48, 54, 73]. This is relevant to human subjects 
with upper extremity WMSDs show increased serum lev-
els of TNFalpha, IL-1beta and soluble receptors, IL-6 or 
macrophage inflammatory proteins [12, 36, 56, 63]. We 
postulate there is a link between elevated serum inflam-
matory cytokines and sickness behaviors occurring in 
subjects with WMSDs as prior studies have found asso-
ciations between high job psychological strain and serum 
levels of C-reactive protein [28]. However, the role of 
inflammation and its negative effects on the CNS is an 
under-investigated topic in the clinical management of 
workers with increased sickness absences, depression or 
persistent pain.
We have developed a unique rat model of voluntary 
repetitive reaching and grasping lever pulling task in 
which prolonged performance of repetitive tasks induces 
exposure-dependent tissue injury, increased inflamma-
tion in involved musculoskeletal tissues that, when left 
untreated, drive degradative and fibrotic tissue changes 
and sensorimotor declines [1, 6, 31, 40]. Treatment of 
rats performing a high repetition high force (HRHF) task 
with ibuprofen or by moving the HRHF rats to an easier 
task attenuated local bone inflammatory and degrada-
tive responses [7, 24, 40], although we have yet to explore 
inflammatory cytokines in other tissues after these inter-
ventions. We hypothesize that these interventions should 
reduce task-induced serum inflammatory cytokine 
responses, for example. Surprisingly, ibuprofen treatment 
attenuated early but not long-term reflexive grip strength 
declines in our model [1, 44], leading us to hypothesize 
that CNS neuroinflammatory processes underlie the 
development, but not the maintenance of pain-related 
behaviors, as previously suggested from surgically-
induced nerve injury studies [39, 57, 67]. This hypothesis 
has not been explored in reference to WMSDs; nor have 
we examined sickness behaviors or their treatment in our 
rat model.
Thus, we evaluated the effectiveness of conservative 
interventions (provision of ibuprofen or switching rats 
from the HRHF task to a reduced force and reach rate 
task for preventing: (1) declines in social interaction with 
a novel juvenile rat; (2) decreased forepaw withdrawal 
threshold; (3) decreased operant reaching and grasp-
ing abilities; (4) increased serum levels of inflammatory 
cytokines and chemokines; and (5) increased neuroin-
flammation in the median nerve, brain and spinal cord. 
Decreased social interaction and exploration are thought 
to be signs of depression in rats and was chosen as a 
measure of sickness behavior [71]. Ibuprofen was cho-
sen as one intervention as it is a common nonsteroidal 
anti-inflammatory drug used world-wide by workers 
experiencing pain [2, 8, 15, 49]. Since long-term ibupro-
fen can have negative side effects [4], we also explored 




Experiments were approved by the Institutional Ani-
mal Care and Use Committee and were in compliance 
with NIH guidelines for the humane care and use of 
laboratory animals. All rats were housed in an AAALAC-
accredited animal facility in separate cages with a 12-h 
light:dark cycle and free access to water, and were pro-
vided with environmental enrichment in their home 
cages (chew toys and tunnels). All rats were handled at 
least 3  days per week by the same handlers to reduce 
investigator-induced stressors. Female Sprague–Dawley 
rats were used since human females have a higher inci-
dence of WMSDs than males [16]. Rats were procured at 
4–7 weeks of age and housed (while being handled until 
onset of experiments at 2.5 months of age (young adults). 
Rats were 3–7  months of age at completion. Behavioral 
procedures were conducted at the same times per day to 
minimize effects related to diurnal factors.
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All but normal control rats were food-restricted to 
body weights of no less than 5% lower than age-matched 
normal controls to motivate interest in food reward 
pellets. Rats were weighed weekly and allowed to gain 
weight similarly across the course of the experiments, as 
they were young adults, as reported previously [7, 40]. 
In addition to food pellet rewards (a 1:1 mix of puri-
fied grain and banana 34  mg flavored pellets; Bioserve, 
NJ, USA), all rats received grain-based Purina rat chow 
daily (control rats also received the same number of food 
reward pellets as task rats). Rats were inspected weekly 
and again post-mortem for presence of illness or tumors 
to reduce confounders for serum cytokine increases 
(none were observed).
A total of 159 rats were used in this study. They 
included:
(a) Normal control rats (NC) euthanized at 1  week 
(n =  21) or at 19 weeks (n =  18) after onset of the 
experiment (the latter for euthanasia at matched time 
points as 12-week HRHF rats), with no training or 
task performance;
(b) Age-matched food-restricted control rats (FRC) 
euthanized at 1 week (n = 9) or at 19 weeks (n = 14) 
after onset of the experiment (the latter for euthana-
sia at matched time points as 12-week HRHF rats), 
with no training or task performance;
(c) Age- and weight-matched food-restricted rats that 
underwent training for 10  min/day for 6  weeks to 
pull to high force levels before euthanasia immedi-
ately post training (TRHF rats, n = 14);
(d) TRHF rats that received 40 mg/kg body weight doses 
of oral ibuprofen, daily, across the entire 6-week 
training period, and then euthanized post training 
(TRHF + IBU rats, n = 12);
(e) TRHF rats that rested after the training period until 
euthanasia at matched time points as 12-week HRHF 
rats (TRHF + Rest, n = 7).
(f ) Untreated TRHF rats that then went on to perform 
a high repetition high force (HRHF) task for 6 or 
12  weeks, untreated (6- and 12-week HRHF rats; 
n = 10 and 15, respectively);
(g) Untreated TRHF rats that then went on to perform 
a HRHF task for 4 weeks, before being administered 
liquid ibuprofen (Children’s Motrin Grape Flavored, 
Johnson & Johnson) in drinking water daily (40 mg/
kg body weight) for 2 or 8 weeks, beginning in week 
5, as described [24], while still continuing to perform 
the HRHF task (6- and 12-week HRHF +  IBU rats; 
n = 12 and 11, respectively); and
(h) Untreated TRHF rats that then went on to perform 
a HRHF task for 4 weeks, that were moved to a low 
repetition low force (LRLF) task for 2 or 8  weeks, 
beginning in week 5, as previously described [7] (6- 
and 12-week HRHF-to-LRLF rats, n  =  5 and 13, 
respectively).
Behavioral apparatuses
Sixteen custom-designed behavioral apparatuses were 
used, as previously described [6, 13] and depicted [55]. 
Briefly, custom-designed force apparati were integrated 
into standard open field boxes placed into larger sound 
dampening boxes (Med Associates, St. Albans, VT). Each 
box had a portal located at the rats’ shoulder height, 
through which the rats reached through and pulled on 
a 1.5 mm metal bar, termed a force lever bar, positioned 
2.5 cm outside of the chamber wall. This bar was attached 
to a miniature tension–compression load cell (Model 
LSB200, Futek Advanced Sensor Technology, Irvine, CA) 
interfaced with a strain-gauge amplifier (Model CSG110, 
Futek). The load cell signal was low pass filtered at 50 Hz 
before being sampled digitally at 100  Hz using Force 
Lever activity software (ENV-118  M, Product Number 
SOF-808, Med Associates) that allowed us to choose 
a set force level to which rats had to pull to receive a 
food reward. Auditory indicators (Med Associates) cued 
the animal to attempt a reach. The rats had to grasp the 
force lever and exert an isometric pull in the correct 
time frame and within target thresholds (defined further 
below). If these criteria were met within a 500 ms cueing 
period, a reward light came on signaling the arrival of a 
45 mg purified formula food pellet (Bioserve, NJ) into a 
trough located at floor height for the animal to lick up.
Training and task regimens
Training and task procedures were as previously 
described [6]. Briefly, all 159 rats were handled for 1 week 
prior to onset of experiments; this week was also the 
onset of food restriction in all but normal control rats. 
Subsets of rats were randomly chosen to serve as nor-
mal controls (n  =  39) or food restricted only controls 
(n = 23) at this time point. The remaining rats (n = 97) 
were trained to pull a lever bar at high force levels during 
a 6-week initial training period of 10 min/day for 5 days/
week. The target high force effort was 55% ± 5% of their 
mean maximum voluntary grasping force (110  ±  5.4 
grams of force (gf ); 1.078 Newton’s). Subsets of the 
trained rats were euthanized immediately post training, 
as either untreated trained only rats (TRHF rats, n = 14), 
trained only rats that rested for 12 weeks (TRHF + Rest, 
n = 7), or trained only rats that received 40 mg/kg body 
weight doses of oral ibuprofen, daily across the entire 
6-week training period (TRHF  +  IBU rats, n  =  12). 
Note, the post training time point is equal to 0 weeks of 
the HRHF task. The remaining 66 trained rats went on 
to perform a high repetition high force (HRHF) lever 
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pulling task rats for 2  h/day and 3  days/week. This task 
was divided into 4, 0.5-h sessions separated by 1.5  h in 
order to avoid satiation. HRHF rats were cued to reach 
at a rate of 4 reaches/min and to grasp and hold a force 
lever bar for at least 15 ms, although a target of 300 ms 
was expected during the 500 ms cueing period, at a target 
force effort of 55 ±  5% of their mean maximum volun-
tary grasping force (1.078 Newton’s). Subsets of HRHF 
rats were randomly chosen to be untreated HRHF rats 
(n = 25), HRHF + IBU rats (n = 23), or HRHF-to-LRLF 
rats (n  =  18), as described above. The ibuprofen treat-
ment began in HRHF task week 5 [40]. HRHF-to-LRLF 
rats were moved to a low repetition low force task, begin-
ning in week 5, that consisted of 2 reaches/min at 15% 
(0.29 Newton’s) of their maximum voluntary grasping 
force, for 2 h/day and 3 days/week [7]. Rats were not pre-
vented from reaching at a higher or lower force than their 
target force; however, if they either undershot the mini-
mum criterion, no food reward was delivered. Thus, the 
animals were allowed to self-regulate their participation 
in task performance, making these voluntary tasks.
Determination of reach performance behaviors in task rats
Force lever data were recorded continuously during 
each task session for later calculation of the depend-
ent variables (reach force and grasp time) via an auto-
mated script (MatLab; Mathworks, Natick, MA). Reach 
force was the mean recordable reach force (in Newton’s) 
applied to the force lever bar for all reaches across a given 
day. Grasp time was the mean average time (in seconds) 
the rats spent pulling on the lever bar for all recordable 
reaches. The mean grasp force and grasp time were cal-
culated over the interval that ended when the force fell 
below 2.5% of baseline. From these data, the mean reach 
impulse (force ×  time) was calculated and reported for 
each individual rat by multiplying the mean reach force 
in Newton’s by the mean grasp time in seconds. Data for 
each variable was calculated on the last day of weeks 1, 
3, 6 and 12. Week 1 was used as the baseline for reach 
performance variables since that was the first week rats 
actually performed the task regimens for 2 h/day, 3 days/
week.
Social interaction behaviors
Adult control, trained or task rats were placed into clean 
and clear plastic chambers with plastic bottoms and 
allowed to acclimate for 10 min. We then timed (in sec-
onds) the duration of social exploration of the adult rat 
towards a novel juvenile rat (4–6  weeks of age) during 
the first 5 min (300 s total) following introduction of the 
juvenile rat. The following were considered as positive 
interactions with the juvenile rat: (1) sniffing of any kind 
(face-to-face or genitoanal), (2) crawling over or under, 
and (3) grooming of one another. Aggression by the adult 
rat towards the juvenile rat was also noted on incidence 
during this 5 min testing period, and included boxing, lat-
eral displays, biting, wrestling and kicking. Such actions 
ended the social interaction session in accordance with 
our Animal Care and Use Committee guidelines, and the 
juvenile rat was removed from the cage immediately (thus, 
physical wounds were avoided). The person carrying out 
the testing was naive to group assignment. The mean inci-
dence per testing session, normalized to number of rats 
tested, is reported. All animals were maintained in micro-
filter topped cages in the housing room to preclude intro-
duction of pheromone cues, and novel juvenile rats were 
brought into the behavioral testing room only prior to this 
testing for the same purpose. The number of novel juve-
nile rats used is not included in the final animal count as 
they were enrolled in other experiments post use.
Forepaw withdrawal response threshold (mechanical 
allodynia)
Forepaw withdrawal behavioral responses to von Frey 
filaments (North Coast Medical, Morgan Hill, CA) were 
assayed as previously described [13]. The force of the small-
est sized filaments (in grams) to which the rats withdrew 
their forepaw after stimulation was considered the response 
threshold. Forepaw von Frey withdrawal threshold data for 
the preferred reach limb only is reported. The person car-
rying out the testing was naive to group assignment.
ELISA analysis of inflammatory cytokines and chemokines 
in serum and the median nerve
Following anesthesia using sodium pentobarbital (i.p., 
120 mg/kg body weight), at 18 h after completion of the 
final task and behavioral testing sessions (to avoid exer-
cise- or acute stress-induced serum cytokine/chemokine 
changes), blood was collected from all rats by cardiac 
puncture using a 23-gauge needle and centrifuged imme-
diately at 1000×g for 20 min at 4 °C. Serum was collected 
and stored at −80 °C until analyzed for 15 cytokines and 
chemokines using a customized multiplex ELISA sys-
tem (Aushon Biosystems Inc., Billerica, MA). Serum 
was assayed for 14 cytokines and chemokines: (a) five 
inflammatory cytokines (IL-1alpha and beta, IL-2, IL-4 
and TNFalpha); (b) a proteic cytokine (IL-6); (c) an anti-
inflammatory cytokine (IL-10); (d) a chemokine that 
activates/macrophages and T cells (interferon gamma, 
IFN-gamma); (e) a chemokine that stimulates differentia-
tion and function of hematopoietic precursor cells from 
various lineages including macrophages (granulocyte 
macrophage–colony stimulating factor, GM–CSF); (f ) 
two C–C motif inflammatory chemokines chemotactic 
for macrophages, neurotrophils and leukocytes [CCL3, 
also known as macrophage inflammatory protein 1 alpha 
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(MIP1a); and CCL20, also known as MIP3a]; and (g) three 
C–X–C motif chemokines secreted by macrophages 
and mast cells [CXCL1, also known as Growth-Related 
Oncogene/Keratinocyte-derived Cytokine (Gro/KC); 
CXCL2, also known as MIP2; and CXCL3 (also known 
as Cytokine-Induced Neutrophil Chemoattractant-2 
(CINC2)]. The array sensitivity of the serum analytes 
tested were (in pg/ml): CCL3 (0.8 pg/ml), CCL20 (1.6 pg/
ml), CXCL1 (0.4  pg/ml), CXCL2 (0.2  pg/ml), CXCL3 
(0.4 pg/ml), GM–CSF (3.1 pg/ml), IL-1alpha (1.5 pg/ml), 
IL-1beta (6.2  pg/ml), IL-2 (6.2  pg/ml), IL-4 (0.8  pg/ml), 
IL-6 (6 pg/ml), IL-10 (0.8 pg/ml), IFN-gamma (6.2 pg/ml) 
and TNFalpha (3.1 pg/ml). All samples were analyzed in 
duplicate in a blinded fashion, and batched as much as 
possible to reduce potential inter-assay variability. Data 
are presented as pg/ml serum.
The median nerve was collected from the forearm and 
palm, flash frozen, homogenized in previously described 
lysis buffer [5] using 0.2 ml microtissue grinders (Whea-
ton, Millville, NJ), and assayed similarly for IL-1beta, 
TNFalpha and IL-10. Data are presented as pg of cytokine 
protein to micrograms of total protein, determine using a 
bicinchoninic acid protein assay kit.
Immunohistochemical analysis of cytokines in brains
Brains of rats were collected and examined immuno-
histochemically from six FRC, nine TRHF, ten 12-week 
HRHF, nine 12-week HRHF + IBU rats, and four HRHF-
to-LRLF rats. For this purpose, rats were euthanized 
with an overdose of sodium pentobarbital (120  mg/kg 
body weight, serum collected for the analysis described 
above, followed by transcardial perfusion with 4% para-
formaldehyde in 0.1 M phosphate buffer (pH 7.4). Brain 
tissues were collected, postfixed by immersion overnight, 
and stored in 30% sucrose for 3 days until cryosectioned 
into 20  µm coronal sections, and mounted on charged 
slides (Fisher Plus). Brain sections, on slides, were 
blocked with 4% goat serum in phosphate buffered saline 
(PBS) and incubated with the following primary anti-
bodies: IL-1beta (Millipore/Chemicon, AB1832P; 1:250 
dilution in PBS) and TNFalpha (Millipore/Chemicon, 
AB1837P; 1:250 dilution in PBS), for overnight at room 
temperature. After washing the sections with PBS, pri-
mary antibodies were visualized using appropriate anti-
rabbit or anti-mouse secondary antibodies (from Jackson 
Immuno) conjugated to diaminobenzidene (DAB, brown 
for IL-1beta; combined with eosin counterstain) or Cy3 
(red fluorescence for TNFalpha), diluted 1:250 in PBS, 
for 2 h at room temperature before washing. Slides were 
washed and then cover-slipped with 80% glycerol in 
phosphate buffer and viewed with Nikon microscopes 
(E800 and E1000) linked to a digital cameras (Q-Imag-
ing Retiga camera) linked to a computer with image 
capturing software (Q-Capture) and image analysis soft-
ware (Bioquant, Nashville, TN). Immunohistochemical 
variability was minimized by performing cytokine immu-
nohistochemistry as a batched assay for each experiment.
Brain sections were examined for cytokine immuno-
reactivity in the following regions: ependymal, brain 
parenchyma surrounding ventricles, hypothalamus and 
anterior cingulate cortex. The percent area fraction of 
brain regions with cytokine immunoreactivity was quan-
tified as previously described, in batched sets by the same 
individual who was blinded to rat treatment. Six meas-
urements were made per section in 3 brain sections per 
rat, each section separated by 140  µm. Measurements 
were made using a set square area of 13.3 cubic microns 
available with the Bioquant image analysis system (Bio-
quant, Nashville, TN).
Preabsorption controls were also performed to demon-
strate if the antibodies bound specifically to the antigen 
of interest. A two to ten fold excess of purified protein 
was pre-incubated with the matching antibody overnight 
at 4  °C (purified recombinant IL-1beta and TNFalpha 
proteins from Millipore were used), the mixture centri-
fuged, and then the pre-absorbed antibody supernatant 
was incubated with the brain sections (after pepsin and 
goat serum treatment) similarly to that described above, 
before washing and incubation with secondary antibod-
ies. No labeling was observed in the tissues for any pre-
absorbed antibody (data not shown). We also performed 
in which serum was substituted for the primary anti-
body, followed by secondary antibodies. No labeling was 
observed as a result of incubation of tissues with serum 
and then secondary antibodies alone (data not shown).
Analysis of spinal cords for TNFalpha, GFAP, substance P 
and neurokinin 1 receptor
Spinal cords were examined immunohistochemically in 
10 FRC, eight 12-week HRHF, six 12-week HRHF + IBU 
and six HRHF-to-LRLF rats. Cervical spinal cord seg-
ments were collected, processed and frozen sectioned, 
as described previously [26]. Spinal cord tissues were 
immunostained using the following primary antibodies: 
anti-TNFalpha (same antibody and dilutions as for brain), 
anti-glial fibrillary acidic protein (GFAP, a marker of acti-
vated astrocytes; Millipore, MAB360; 1:800 dilution in 
PBS), anti-substance P (Millipore/Chemicon AB1556, 
1:250 dilution in PBS) and anti-neurokinin-1 receptor 
(NK-1R; Millipore/Chemicon AB5060, 1:1000 dilution 
in PBS), as previously described [26, 27]. Preabsorption 
controls or no primary antibody controls were performed 
as described above or as described previously [25, 31]. 
The percent area fraction of cervical spinal cord regions 
with immunoreactivity for each analyte was quantified, 
as previously described in detail [26, 27].
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Availability of data and materials
There is no code and no biological materials to share. All 
relevant raw data analyzed during the current study are 
available from the corresponding author on reasonable 
request.
Statistical analyses
Results are expressed as mean and standard error of the 
mean (SEM). All statistical analyses and calculations are 
derived using the XLStat statistical software to assay for 
repeated measures behavioral data with unequal num-
bers per group, followed by the Tukey post hoc correction 
method for multiple comparisons. First, a mixed-effects 
model with repeated measures was used to determine 
effects of 5% food restriction on behaviors in FRC ver-
sus NC rats with free access to food across time, with the 
factors group and time in experiment (1 vs. 19  weeks). 
Mixed-effects models with repeated measures were then 
used for behavioral assays occurring across weeks with 
the factors group and week. Prism Graphpad statistical 
software was used to assay for serum and tissue data, fol-
lowed by the Bonferroni or Tukey correction methods for 
multiple comparisons. Serum was first analyzed using the 
factors group and week to determine which had the high-
est induced levels, followed by analysis using the factors 
treatment and week to determine effects on selected indi-
vidual serum cytokines. One-way ANOVAs were used to 
assess brain, spinal cord and median nerve cytokine and/
or GFAP immunoexpression or levels between groups. 
Two-way ANOVAs were used to compare immunoex-
pression of substance P and neurokinin 1 receptor in the 
spinal cord using the factors treatment and week. For 
conciseness, details of significant ANOVA and posthoc 
results are presented in individual figure panels. Adjusted 
p values are reported, and an adjusted p value of <0.05 
was considered significant for all analyses.
Results
Social interaction declines occurring in TRHF and HRHF rats 
are ameliorated with ibuprofen or move to a low demand 
task
The duration of social interaction with a novel juvenile rat 
declined precipitously with training to high force levels 
(TRHF rats and 0-week HRHF time point) and remained 
decreased in HRHF rats through week 12, compared to 
age-matched FRC rats (Fig. 1a). This response was ame-
liorated in TRHF + IBU rats, TRHF + Rest rats, 6-week 
HRHF  +  IBU and HRHF-to-LRLF rats, and 12-week 
HRHF +  IBU rats, compared to age-matched untreated 
TRHF or HRHF rats (Fig. 1a). Duration of social interac-
tion was near control levels in 12-week HRHF-to-LRLF 
rats, although not significantly improved from 12-week 
HRHF levels.
Aggression increased immediately post training, and 
in untreated 6- and 12-week HRHF rats, compared to 
FRC rats (Fig.  1b). Ibuprofen attenuated this increase 
in TRHF  +  IBU rats and 6-week HRHF  +  IBU rats, 
compared to untreated TRHF and HRHF rats, respec-
tively (Fig.  1b). The 12-week TRHF  +  Rest, 12-week 
HRHF  +  IBU and HRHF-to-LRLF rats showed similar 
incidence of aggression as FRC rats (Fig. 1b).
Mechanical allodynia present in TRHF and HRHF rats 
is attenuated in TRHF + IBU rats, but not by secondary 
intervention task rats
The size of von frey filament needed to elicit a forepaw 
withdrawal response declined precipitously after train-
ing in TRHF and 0-week HRHF rats, and remained 
decreased in HRHF rats through week 12 (indicative of 
mechanical allodynia), compared to age-matched FRC 
rats (Fig.  1c). This response recovered towards control 
levels in TRHF + IBU rats and in TRHF + Rest rats at 6 
and 12 weeks of rest, although neither were significantly 
different from untreated trained or task rats. In contrast, 
HRHF  +  IBU and HRHF-to-LRLF rats showed similar 
low threshold levels as untreated HRHF rats at both time 
points assayed (Fig. 1c).
Reduced HRHF task performance abilities were only 
partially rescued by ibuprofen
The mean reach impulse of untreated HRHF rats was 
lower than target levels throughout all weeks of task per-
formance (Fig.  1d). Figure  1e depicts a successful reach 
occurring within the correct time frame and to the tar-
get force levels, and dispensal of a food reward. Figure 1f 
depicts a representative and often occurring unsuccessful 
reach by a 6-week HRHF rat. The rat pulled several times 
within one cueing period of 500 ms, yet each reach failed 
to meet the target force threshold, suggestive of discom-
fort. As a consequence, no food reward was dispensed 
during this cueing cycle. Ibuprofen treatment improved 
the mean reach impulse in HRHF  +  IBU rats in week 
6, compared to their week 1 levels and untreated HRHF 
rats (Fig.  1d). However, this improvement was transient 
and their mean reach impulse declined to untreated lev-
els by week 12, suggestive of discomfort. HRHF-to-LRLF 
rats showed an appropriate decrease in reach impulse by 
week 12 to low force reach impulse levels (Fig. 1d).
Training to high force (TRHF) and extended HRHF task 
performance increased inflammatory cytokines in serum 
and brain; changes attenuated by the interventions
No differences in serum cytokine/chemokine levels 
were observed in the NC versus FRC rats at 1 week after 
the onset of experiments, or at matched time points as 
12-week HRHF rats (Additional file 1: Figure S1A and B). 
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In contrast, two way ANOVAs using the factors cytokine 
and group showed that IL-1beta, IL-6 and TNFalpha 
increased the most with training or task performance, 
compared to the other cytokines and chemokines assayed 
(Additional file 1: Figure S1).
Follow-up two-way ANOVAS on individual cytokines 
revealed that the initial training increased serum lev-
els of IL-1beta and IL-6 in TRHF rats, compared to 
FRC rats (Fig.  2a, b). CXCL1 (Gro/KC) also increased 
with training, although not significantly (Fig.  2c). 
These training-induced increases were attenuated in 
TRHF  +  IBU rats, compared to untreated TRHF rats 
(Fig.  2a–c). Serum IL-1beta levels resolved over time in 
HRHF task rats to FRC levels. IL-6 remained increased 
in 6-week HRHF rats, compared to FRC rats, although 
it resolved towards control levels by week 12 (Fig.  2b). 
Serum CXCL1 (Gro/KC) and TNFalpha levels were 
increased in 6- and 12-week HRHF rats above FRC lev-
els (Fig.  3C, D); both were significantly attenuated in 
HRHF +  IBU rats (Fig.  2c, d). 12-week HRHF-to-LRLF 
Fig. 2 Serum levels of several cytokines and chemokines, assayed using multiplex ELISA. Results of two‑way ANOVAs for each cytokine are shown 
in each panel, using the factors treatment group and week of experiment. Serum levels of a IL‑1beta, b IL‑6, c CSCL1 (Gro/KC), d TNFalpha, e CCL20 
(MIP3a), and f IFNgamma are shown for each group, across weeks of training and task performance, as indicated. *p < 0.05, compared to food 
restricted control (FRC) rats euthanized after 1 week of food restriction; †p < 0.05, compared to age‑matched untreated TRHF or untreated HRHF rats
(See figure on previous page.) 
Fig. 1 Duration of social interaction, aggression, forepaw withdrawal behavioral changes and reach performance abilities. a Duration of positive 
social interaction (in seconds) of adult rats with a novel juvenile rat during a 300 s observation period. b Incidence of aggression of the adult rat 
with a novel juvenile rat during social interaction period (which ended the test, thus lowering the duration of positive social interaction in a). c Fore‑
paw withdrawal response to light probing of glabrous skin at midpoint of forepaw. Y‑axis shows size of von Frey filament (in grams) required to elicit 
a withdrawal response (mean of 5 probings shown). d Reach impulse (Newton’s of reach force multiplied by grasp time in seconds). HRHF and LRLF 
targets are indicated by dashed lines. e Example of a successful reach. The upper orange line indicates the maximum force threshold, the blue line 
depicts the lower force threshold; the green line depicts the target force threshold; and the pink line above the time marker shows the force deflec‑
tion. The reward line shows that a food reward was delivered to a trough for rats to lick up. f Example of three unsuccessful reaches in one 500 ms 
cueing cycle, in which all reaches were below the target threshold (green line); thus, no food reward was dispensed. Results of two‑way ANOVAs for 
each behavioral parameter are shown. *p < 0.05 in a–c, compared to age‑matched FRC rats; **p < 0.01 in d, compared to week 1 results of same 
group; †,††p < 0.05 and p < 0.01, respectively, compared to age‑matched untreated HRHF rats
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Fig. 3 Inflammatory cytokine immunoreactivity in brain ependymal and endothelial cells. A–C There was an absence of IL‑1beta and TNFalpha 
in these cell types in FRC rat brains. D–F IL‑1beta and TNFalpha immunoreactivity increased in these cell types in 12‑week HRHF rats. In D and E, 
arrows indicate positively stained ependymal cells surrounding the ventricle as well as small stained glial‑like cells within the brain parenchyma. In 
F, inset shows IL‑1beta stained endothelial cell. G, H Percent area with IL‑1beta and TNFalpha immunoreactivity, respectively, in ependymal cells. 
Results for one‑way ANOVAs are shown. **p < 0.01, compared to FRC rats; †p < 0.05, compared to untreated HRHF rats
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rats showed reduced levels of TNFalpha, compared 
to untreated HRHF rats, although CXCL1 remained 
increased increased in this group, compared to FRC 
rats (Fig. 2c, d). By week 12 of HRHF task performance, 
serum levels of CCL20 (MIP3a) and IFNgamma were also 
increased above control levels (Fig.  2e, f ). Both second-
ary interventions successfully attenuated these increases 
by week 12 to control levels (Fig.  2e, f ). The 12-week 
TRHF + Rest rats also showed control levels of inflam-
matory cytokines and chemokines (data not shown).
Brains were collected and examined for IL-1beta and 
TNFalpha immunoreactivity. In FRC rats, an absence 
or only low levels of immunoreactivity were observed 
(Fig. 3A–C, G, H). In contrast, 12-week HRHF rat brains 
showed increased immunoreactivity for both cytokines 
in ependymal cells surrounding all ventricles, small 
glial-like cells adjacent to the ventricles, endothelial 
cells (Fig.  3D–F), and choroid plexus (not shown). The 
endothelial cells were scattered throughout the brain. 
No increased immunoreactivity for IL-1beta or TNFal-
pha were observed in the hypothalamus of any group, 
although low levels of IL-1beta staining was observed 
in the CA3 region of the hippocampus in 3 of 8 of the 
12-week HRHF rats (data not shown). Quantification of 
IL-1beta and TNFalpha immunoreactivity in ependy-
mal cells showed increases in TRHF and 12-week HRHF 
rats, compared to FRC rats, and significant attenuation of 
each in 12-week HRHF + IBU and HRHF-to-LRLF rats, 
compared to untreated HRHF rats (Fig. 3G, H). Cytokine 
immunostaining was also decreased in TRHF  +  IBU 
rat brains, compared to untreated TRHF rats (data not 
shown).
HRHF task performance increased inflammatory cytokines 
in the median nerve, increases attenuated by the 
secondary interventions
In the median nerve at the level of the wrist, increased 
immunoexpression of TNFalpha was observed in TRHF 
rats, but not in TRHF + IBU rats (Fig. 4A vs. B). ELISA 
analysis of the median nerve revealed increased IL-1beta 
and TNFalpha in HRHF rats, compared to FRC rats, and 
decreased levels in 12-week HRHF + IBU and HRHF-to-
LRLF rats (Fig. 4C, D). There were no significant differ-
ences in IL-10 across the groups (data not shown).
HRHF task performance increased inflammatory cytokines, 
GFAP, substance P and NK‑1 in spinal cord dorsal horns, 
increases that the secondary interventions failed to fully 
attenuate
In dorsal horns of cervical spinal cord segments, 
increased immunoexpression of substance P and its main 
receptor, neurokinin-1 receptor (NK-1R), was observed 
in 6- and 12-week HRHF rats, compared to FRC rats 
(Fig.  5). Such spinal cord changes were not observed in 
TRHF rats (Fig.  5B, F, I, J). Substance P immunostain-
ing remained increased in 6- and 12-week HRHF + IBU 
and HRHF-to-LRLF rats, compared to FRC rats (Fig. 5I). 
NK-1R immunostaining was partially attenuated 
(although not to control levels) in 12-week HRHF + IBU 
and HRHF-to-LRLF rats (Fig. 5J).
Fig. 4 Inflammatory cytokines in the median nerve. A, B TNFalpha 
immunoreactivity in the median nerve at the level of the wrist of 
TRHF and TRHF + IBU rats, respectively. Images were taken with a 
40× objective. C, D IL‑1alpha and TNFalpha levels in the median 
nerve, respectively, assayed using ELISA. Results for one‑way ANOVAs 
are shown. **p < 0.01, compared to age‑matched untreated FRC rats; 
†p < 0.05, compared to age‑matched untreated HRHF rats
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Based on these results, we explored possible spinal 
cord sensitization changes further by examining cervical 
spinal cord segments of control and task rats for TNFal-
pha increases and astrocyte activation. In superficial 
lamina of dorsal horns of cervical spinal cord segments, 
increased immunoexpression of TNFalpha was observed 
as increased punctate staining in 12-week HRHF rats, 
compared to FRC rats (Fig. 6D vs. A). Increased immu-
noexpression of GFAP was observed in this same region 
in 12-week HRHF rats, compared to FRC rats (Fig. 6E, H 
vs. B, H). Some TNFalpha-positive cell profiles co-local-
ized with the GFAP immunoexpression (Fig.  6C, F and 
Fig. 6 TNFalpha and GFAP immunostaining in the superficial lamina (lamina I and II) of dorsal horns of the spinal cord at cervical 7 segmental level. 
A–C Representative immunoreactivity in FRC rat for TNFalpha, GFAP, or both together. Arrow indicates same cells in each panel, showing a lack 
of overlap between TNFalpha and GFAP. Scale bars 50 μm, and applies to all other panels except insets. D–F Representative immunoreactivity in 
12‑week HRHF rat for TNFalpha, GFAP, or both together. Arrows and lettering a–c indicate cells shown enlarged in insets of each panel and depicts 
cells with TNFalpha and GFAP co‑localization. G, H Quantification of percent area with TNFalpha and GFAP immunostaining. **p < 0.01, compared to 
food restricted control (FRC) rats
(See figure on previous page.) 
Fig. 5 Substance P and NK‑1R immunostaining in superficial lamina of dorsal horns of spinal cords at cervical 7 segmental level. A–D Representa‑
tive images of dorsal horns showing punctuate substance P immunofluorescence (green) staining distributed across entire zone, medial to lateral 
(right to left side, respectively, in each panel). 12‑week HRHF and HRHF + IBU rats show increased immunoexpression laterally. Insets in D shows loca‑
tion of substance P immunostaining at low power. Scale bars 50 μm, and applies to all panels except insets. E–H Dorsal horns showing neurokinin‑1 
receptor (NK‑1R) immunostaining (red). Inset in E shows localization of NK‑1R immunostaining at low power. I, J Quantification of percent area with 
immunofluorescence staining for substance P and NK‑1R, respectively, in C7 dorsal horn superficial lamina. Results for two‑way ANOVAs are shown. 
*p < 0.05, compared to age‑matched untreated FRC rats
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insets). These increases were not significantly attenuated 
by either secondary intervention (Fig. 6G, H).
Increased TNFalpha immunoexpression was also 
observed in deeper dorsal horn lamina and in the ven-
tral horns of cervical spinal cord segments of 12-week 
HRHF and HRHF  +  IBU rats, compared to FRC rats 
(Fig. 7). The TNFalpha immunostaining in these regions 
was within NeuN immunopositive neurons (Fig.  7C, D, 
H insets, G). The TNFalpha immunoexpression in deeper 
dorsal horn lamina was significantly reduced in 12-week 
HRHF-to-LRLF rats, compared to untreated HRHF rats 
(Fig. 7I). TNFalpha immunostaining in ventral horn neu-
rons remained increased in both secondary intervention 
groups, compared to FRC rats, and was not significantly 
reduced from untreated HRHF rat levels (Fig. 7D, H, J).
Discussion
We show here for the first time in an operant model of 
work-related musculoskeletal disorders that extended 
performance of a high demand reaching and grasping 
task induced aggression and social interaction declines, 
concomitant with chronic brain neuroinflammatory 
changes. We also observed persistent increases in serum 
levels of several inflammatory cytokines and chemokines, 
and increased TNFalpha in the median nerve. The 
responses were attenuated by ibuprofen treatment (at 
prophylactic and secondary administration time points) 
and an ergonomic task reduction intervention. These 
findings novelly suggest that chronic inflammatory 
responses induced by prolonged performance of high 
physical demand tasks mediate the development and 
maintenance of subsets of sickness behaviors. However, 
HRHF task-induced pain related behaviors persisted, 
even after the treatments, perhaps because spinal cord 
neuroinflammation and neurotransmitter changes were 
not effectively reduced by these secondary interventions.
Human workers exposed to repeated workplace expo-
sures to hand intensive tasks at high force and activ-
ity levels, have increased risk of new-onset pain [34, 
37]. Human workers with WMSDs are also at risk for 
Fig. 7 TNFalpha immunostaining (green) in dorsal horn deep lamina (DH) and ventral horns (VH) of the spinal cord at cervical 7 segmental level. 
NeuN, a nuclear stain, shown in red. A, E Representative immunoreactivity in FRC rat. B, F Representative immunoreactivity in untreated 12‑week 
HRHF rats. Arrow in B indicates same cells as in upper inset, showing TNFalpha in NeuN stained neurons. Lower insets shows areas of assay for dorsal 
horn deep lamina and ventral horns, respectively. C, G Representative immunoreactivity in 12‑week HRHF + IBU rat. Inset in C shows TNFalpha in 
NeuN stained neurons. D, H Representative immunoreactivity in 12‑week HRHF‑to‑LRLF rat. Insets show TNFalpha staining in NeuN stained neurons. 
I, J Quantification of number of TNFalpha immunostained cells per mm2. **,*p < 0.05 and p < 0.01, compared to food restricted control (FRC) rats; 
††p < 0.01, compared to age‑matched untreated HRHF rats
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developing increased depression, aggression, chronic 
pain and reduced work performance abilities [23, 29, 58, 
72]. Thus, behavioral findings (Fig. 1) from our rat model 
match the human condition. Epidemiological studies show 
that high psychological job demands and low job control 
are risk factors for developing upper limb WMSDs [9, 47, 
51]. Our findings here also indicate that training to high 
physical force levels induces social interaction declines, 
aggression and pain-related behaviors. The improvement 
in TRHF + Rest rats, compared to untreated HRHF rats, 
further supports continued high force work as an induc-
ing physical risk factor. Prophylactic ibuprofen treatment 
provided during training was also effective, indicating 
that inflammatory mechanisms are involved in the devel-
opment of these behavioral declines. Both secondary 
interventions ameliorated incidence of aggression and 
improved duration of social interaction. However, neither 
attenuated the forepaw mechanical allodynia, and second-
ary ibuprofen treatment only transiently improved reach 
impulse abilities. Surgically induced nerve injury studies 
have shown that inflammatory cytokine increases within 
injured nerves are responsible for the development of 
pain-related behaviors, but not their maintenance [39, 
57, 67]. From this, we suggest that provision of secondary 
interventions beginning in task week 5 was too late to res-
cue pain-related behaviors as nerve TNFalpha increases 
had already occurred (Fig. 4).
Human subjects with upper limb WMSDs of duration 
similar to this current study (≤12 weeks) have increased 
pain symptoms that correlate with increased serum 
TNFalpha, MIP1alpha and MIP1beta [12, 56, 64]. These 
were cross-sectional studies, and their findings differed 
from others examining serum cytokines in human sub-
jects with MSDs of shorter or longer duration, in which 
either only soluble receptors of the IL-1 family or IL-6 
were detected (≤1 month) or no cytokines were detected 
in serum at the time of median nerve decompression 
surgery [32, 46, 63]. A recent systematic review suggests 
the need for longitudinal and broader biomarker stud-
ies [35]. Therefore, we expanded beyond our past study 
of HRHF rats in which we examined only 3 cytokines in 
serum (IL-1alpha, IL-1beta and TNFalpha) at two time 
points [7], to examine 14 cytokines/chemokines across 
the 4.75  month span of this experiment. We observed 
considerable differences in the systemic inflammatory 
response over time. The initial training induced increased 
levels of IL-1beta and IL-6 (Fig. 2). Then, serum levels of 
IL-1beta resolved immediately post training, IL-6 levels 
resolved by week 12, CXCL1 and TNFalpha increases 
began in week 6, and by HRHF task week 12 there were 
increases in CXCL1, TNFalpha, CCL20 and IFNgamma. 
Thus, the time of serum collection affects the outcome in 
chronic studies. Each treatment (prophylactic ibuprofen, 
rest, and secondary interventions) successfully attenuated 
the increases in serum inflammatory cytokines (with the 
exception of CXCL1 levels which remained elevated in 
HRHF-to-LRLF rats), in parallel with decreases in aggres-
sion and improvement in social interaction time, the latter 
suggestive of an association between these findings.
Presence of tissue damage activates the immune sys-
tem to induce local release of inflammatory cytokines 
and other mediators which can overspill into the circu-
latory system to drive widespread activation of defense 
pathways, such as the sickness behavior pathways [10]. 
The median nerve may be one source of the circulating 
TNFalpha (Fig. 4). We have previously reported median 
nerve injury in HRHF task rats in the form of myelin 
degradation and reduced nerve conduction velocity [13]. 
We have also shown increased muscle and bone levels 
of inflammatory cytokines in 12-week HRHF rats [6], 
and that their levels in bone are reduced by the second-
ary ibuprofen and ergonomic task reduction treatments 
[7, 24, 40]. Central brain production of inflammatory 
cytokines, such as the increased immunoexpression of 
IL-1beta and TNFalpha in ependymal and endothelial 
cells (Fig.  3) may also be maintaining their increase in 
serum in a bi-directional manner [70].
Known mechanisms by which peripheral pro-inflamma-
tory cytokines provoke CNS neuroinflammation include 
diffusion from the circulatory system into the brain 
through blood–brain-barrier-deficient brain areas, active 
transport into the CNS by endothelial cells, and/or acti-
vation of blood brain barrier cells that then activate neu-
rons, astrocytes or microglia [48, 54, 73]. The increased 
inflammatory cytokine immunoexpression in ependymal 
cells supports a diffusion mechanism in our model, while 
the increased immunoexpression of cytokines in endothe-
lial cells suggests activated endothelial cell-to-astrocyte 
cell signaling. Our behavior and brain immunoexpression 
findings are in line with others showing reduced social 
interaction and increased aggression after exogenous 
administration of TNFalpha or IL-1beta [69, 75], and 
involvement of ependymal, endothelia and astrocytic cells 
in sickness behaviors [19, 66], respectively. Both second-
ary interventions successfully attenuated serum and brain 
inflammatory cytokine increases, social behavior declines 
and aggression, supporting an involvement of inflamma-
tory cytokines in their development and maintenance as 
shown previously in models of other disorders [20, 42, 
60]. Other labs have also shown that the development of 
such behaviors can be prevented or reversed by treatments 
with NSAIDS or more specific COX 1/2 inhibitors [21, 53, 
68]. We add here that removal of the inducing factor (the 
high force task) using rest or an ergonomic task reduction, 
also successfully reduced serum and brain inflammatory 
responses and ameliorated the social interaction declines.
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Increased inflammatory cytokines in injured periph-
eral nerves are known to induce spinal cord central sen-
sitization, including increased inflammatory cytokines, 
substance P and NK-1R immunoexpression in spinal 
cord astrocytes, microglia and neurons [26, 43, 65]. The 
systemic inflammatory responses may also be contrib-
uting to spinal cord sensitization [30]. Central sensitiza-
tion responses in the spinal cord are known to contribute 
heavily to persistent and chronic pain behaviors [41, 74]. 
Our findings of persistent reach performance declines 
in HRHF rats shown here and previously [44], as well as 
forepaw mechanical allodynia in treated task animals, 
concomitant with persistent spinal cord sensitization, 
may explain epidemiological reports of failure of many 
common secondary interventions (including ibuprofen) 
in attenuating pain in subjects with chronic MSDs [17, 
58, 61]. The effectiveness of multifaceted interventions 
or other anti-inflammatory drugs should be explored, as 
discussed further below.
While the strengths of this study include a longitudi-
nal study in age-matched animals, the use of an oper-
ant model, and the ability to examine both peripheral 
and central neural tissues, it is still nevertheless a rat 
model. Translation of some aspects of the study needs 
to be performed in humans with upper extremity work-
related injuries. Also, multiple molecules or pathways 
may be activated and thereby serve as contributors to the 
observed sensorimotor declines. Ibuprofen reduces COX 
and prostaglandin E2 production and pain effectively, but 
not leukotriene B4 production [59]. Leukotrienes can 
contribute to nociceptive-related responses and spinal 
cord sensitization changes following peripheral nerve 
injury [3, 22, 45]. Broader anti-inflammatory drugs may 
be needed for more effective treatments of repetitive 
injury induced pain related behaviors.
Conclusions
Performance of a high demand work task at high reach 
rate and grasping force levels induced increased inflam-
matory cytokines in serum as well as several peripheral 
and central neuroinflammatory responses. The periph-
eral inflammatory responses appeared to alter social 
interaction behaviors via humoral-to-brain neuroin-
flammation mechanisms, and to increase pain-related 
behaviors via peripheral nerve-to-spinal cord sensitiza-
tion mechanisms. The social interaction declines and 
increased aggression were effectively reduced by com-
mon interventions (rest, ibuprofen and ergonomic task 
reduction). However, persistent behavioral indices of dis-
comfort were associated with persistent spinal cord sen-
sitization, indicating the continued need for prevention 
or more effective treatments.
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